Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA).
The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.
Dr. Reddy's Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.5337.3 as compared to the previous close of Rs. 5270.2. The total number of shares traded during the day was 23721 in over 2194 trades.
The stock hit an intraday high of Rs. 5360 and intraday low of 5279.3. The net turnover during the day was Rs. 126461377.